Cyrano Therapeutics
Washington
About Cyrano Therapeutics
Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $21.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2024)
- Website: cyranotherapeutics.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cyrano-therapeutics-142714 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.